📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Serodus

1.1 - Company Overview

Serodus Logo

Serodus

Headquarter: Norway
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of Scandinavian drug development focused on unmet needs in diabetes and diabetic comorbidities. In-licenses early-stage candidates and partners after Phase II proof of clinical effect. Pipeline includes SER150, an anti-inflammatory targeting diabetic kidney disease via thromboxane synthase inhibition and receptor blockade, and SER140, an IL-1β receptor antagonist for diabetic kidney disease.

Products and services

  • Early-Stage In-Licensing & Phase II Partnering: Architects programs that in-license drug candidates early, then partners after human clinical Phase II efficacy is demonstrated for unmet diabetes and comorbidity therapies
  • Phase II-centric
  • SER150: An anti-inflammatory compound targeting diabetic kidney disease by inhibiting thromboxane synthase and blocking the thromboxane receptor to reduce renal impairment progression
  • Enzyme-targeted
  • SER140: An IL-1β receptor antagonist engineered to treat diabetic kidney disease by inhibiting diabetes-induced inflammatory processes within the kidney
  • Receptor-specific

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Serodus

TheraSense Logo

TheraSense

HQ: United States Website
  • Description: Provider of easy-to-use glucose self-monitoring systems for people with diabetes, using proprietary technologies to dramatically reduce the pain of testing. Products are less painful than current offerings; FreeStyle, the first product, accurately measures glucose levels in blood.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full TheraSense company profile →
Biodel Logo

Biodel

HQ: United States Website
  • Description: Provider of biopharmaceutical therapeutics for the treatment of diabetes, focused on developing and commercializing diabetes treatments.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Biodel company profile →
Sensulin Logo

Sensulin

HQ: United States Website
  • Description: Provider of diabetes drug discovery focused on a once-a-day glucose-responsive insulin for type 1 and type 2 diabetes, designed to reduce hypoglycemia risk and long-term complications.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sensulin company profile →
CanAm Care Logo

CanAm Care

HQ: United States Website
  • Description: Provider of medical equipment and devices as a healthcare company, engaged in manufacturing and retail.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CanAm Care company profile →
CureDM Logo

CureDM

HQ: United States Website
  • Description: Provider of biopharmaceutical therapies that may prevent, ameliorate or reverse diabetes, including Human proIslet Peptide (HIP), a novel human peptide developed to regenerate insulin-producing islets in the pancreas and potentially restore pancreatic function without stem cells, with the goal of allowing discontinuation of insulin.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CureDM company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Serodus

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Serodus

2.2 - Growth funds investing in similar companies to Serodus

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Serodus

4.2 - Public trading comparable groups for Serodus

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Serodus

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Serodus

What does Serodus do?

Serodus is a provider of Scandinavian drug development focused on unmet needs in diabetes and diabetic comorbidities. In-licenses early-stage candidates and partners after Phase II proof of clinical effect. Pipeline includes SER150, an anti-inflammatory targeting diabetic kidney disease via thromboxane synthase inhibition and receptor blockade, and SER140, an IL-1β receptor antagonist for diabetic kidney disease.

Who are Serodus's competitors?

Serodus's competitors and similar companies include TheraSense, Biodel, Sensulin, CanAm Care, and CureDM.

Where is Serodus headquartered?

Serodus is headquartered in Norway.

How many employees does Serodus have?

Serodus has 1,000 employees 🔒.

When was Serodus founded?

Serodus was founded in 2010 🔒.

What sector and industry vertical is Serodus in?

Serodus is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Serodus

Who are the top strategic acquirers in Serodus's sector and industry

Top strategic M&A buyers and acquirers in Serodus's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Serodus?

Top strategic M&A buyers groups and sectors for Serodus include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Serodus's sector and industry vertical

Which are the top PE firms investing in Serodus's sector and industry vertical?

Top PE firms investing in Serodus's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Serodus's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Serodus's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Serodus's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Serodus include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Serodus's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Serodus?

The key public trading comparables and valuation benchmarks for Serodus include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Serodus for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Serodus with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Serodus's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Serodus with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Serodus's' sector and industry vertical?

Access recent funding rounds and capital raises in Serodus's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Serodus